Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement: Results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry

Peter B. Berger, Neal S. Kleiman, Michael J. Pencina, Wen Hua Hsieh, Steven R. Steinhubl, Allen Jeremias, Ali Sonel, Kevin Browne, Greg Barseness, David J. Cohen

Research output: Contribution to journalArticle

114 Scopus citations

Abstract

Objectives This study sought to determine the frequency of noncardiac surgery and adverse post-operative events among patients who recently received a drug-eluting stent (DES) following noncardiac surgery. Background Little is known about frequency of and risks associated with noncardiac surgery after DES implantation. Methods In the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) registry, consecutive patients who underwent attempted stent placement at 42 hospitals between July 2004 and September 2005 were enrolled and followed for 1 year. In this study, we analyzed patients who received <1 DES to determine the frequency of noncardiac surgery and cardiac death, myocardial infarction, or stent thrombosis in the following week. Results Among 4,637 DES recipients, 206 (4.4%) underwent major noncardiac surgery in the following year (median days to surgery: 179 [interquartile range 112 to 266 days; range 13 to 360 days]). Overall, stent use averaged 1.5 per patient. The most frequent operations were orthopedic (36%), abdominal (31%), and vascular (20%). Compared with patients who did not undergo surgery, those who did were older, more likely to be women, and have had a prior stroke; the frequencies of prior myocardial infarction, prior coronary artery bypass graft, and diabetes were similar, as were left ventricular ejection fraction and indication for percutaneous coronary intervention. In the 7 days after surgery, 4 patients had a cardiac death, myocardial infarction, or stent thrombosis (1.9% [exact 95% confidence interval (CI): 0.5% to 4.9%]). The risk of the composite outcome was increased 27-fold in the week following noncardiac surgery compared with any other week after stent implantation (hazard ratio [HR]: 27.3 [95% CI: 10.0 to 74.2], p < 0.001). Conclusions The frequency of major noncardiac surgery in the year after DES placement is >4%. Although the overall risk of adverse outcomes was less than previously reported when surgery is performed months after DES placement, it is significantly increased in the week after major noncardiac surgery.

Original languageEnglish (US)
Pages (from-to)920-927
Number of pages8
JournalJACC: Cardiovascular Interventions
Volume3
Issue number9
DOIs
StatePublished - Sep 2010

Keywords

  • adverse events
  • drug-eluting stent
  • noncardiac surgery

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement: Results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry'. Together they form a unique fingerprint.

Cite this